October 10, 2015
Recommended Topic Related To:


"On May 10, the U.S. Food and Drug Administration approved Nymalize, a new nimodipine oral solution, to treat patients experiencing symptoms resulting from ruptured blood vessels in the brain (subarachnoid hemorrhage). Nimodipine previously was av"...


(nimodipine) Oral Solution


NYMALIZE contains nimodipine, a dihydropyridine calcium channel blocker. Nimodipine is isopropyl 2methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate. It has a molecular weight of 418.5 and a molecular formula of C21H26N2O7. The structural formula is:

NYMALIZE (nimodipine) Structural Formula Illustration


Nimodipine is a yellow crystalline substance, practically insoluble in water.

NYMALIZE Oral Solution contains 60 mg of nimodipine per 20 mL. In addition, the oral solution contains the following inactive ingredients: ethanol, glycerin, methylparaben, polyethylene glycol, sodium phosphate monobasic, sodium phosphate dibasic, and water.

Last reviewed on RxList: 5/23/2013
This monograph has been modified to include the generic and brand name in many instances.

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

WebMD Daily

Get breaking medical news.